PODD gains momentum as Omnipod 5 adoption accelerates, margins scale, and earnings estimates rise despite macro and concentration risks.

Despite an Insulet stake reduction by a major fund, analysts maintain a 'Moderate Buy' rating. Discover why institutional ...

Many investors pay attention to mid-cap stocks because they have established business models and expansive market ...

Despite record beef prices linked to a country-wide cattle shortage, long lines formed at butcher shops Tuesday. TMJ4 spoke with some in line to hear how the price hike is affecting their wallets.

Insulet Corporation (NASDAQ:PODD) is one of the best growth stocks to buy in 2026. On December 18, Truist lowered the firm’s ...

Insulet Corporation (NASDAQ:PODD) develops, manufactures, and sells insulin delivery systems for people with ...

In a report released on December 16, Shagun Singh Chadha from RBC Capital maintained a Buy rating on Insulet, with a price target of $380.00. The company’s shares closed yesterday at $288.73.

Insulet delivers strong fundamentals, with robust revenue growth, high margins, and impressive returns on capital, driven by Omnipod's success. PODD's Q3 results were strong, featuring record revenues ...

Insulet Corp. closed 19.55% short of its 52-week high of $354.88, which the company achieved on November 20th.

Fintel reports that on November 19, 2025, UBS upgraded their outlook for Insulet (NasdaqGS:PODD) from Neutral to Buy. Analyst Price Forecast Suggests 9.42% Upside As of November 17, 2025, the average ...